CoChat
Sign Up
Cited by 101

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Self-crosslinkable chitosan-hyaluronic acid dialdehyde nanoparticles for CD44-targeted siRNA delivery to treat bladder cancer

Liang, Ye, Wang, Yonghua, Wang, Liping, Liang, Zhijuan, Li, Dan, Xu, Xiaoyu, Chen, Yuanbin, Yang, Xuecheng, Zhang, Hongbo, Niu, Haitao·2021·Bioactive Materials
DOI 10.1016/j.bioactmat.2020.08.019PMC PMC7490593
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bioactmat.2020.08.019

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical abstract
Graphical abstract CC BY-NC-ND · PubMed Central
Fig. 1 CD44 expression in bladder tissues and cells and effective Bcl2-siRNA sequences that were screened. A: Immunohistochemistry assays were performed to detect CD44 receptor expression in bladder tumours and normal tissues. B: CD44 expression in bladder cancer cell lines (T24, 5637) and the normal bladder cell line (SV-HUC-1) was detected by western blotting. C: The effective interference sequences were screened for the down regulation of the targeted gene, Bcl2. The siRNA1, 2, 3 are targeted to the sites of 528, 928, 1014 of Bcl2 respectively. All quantification of protein levels was normalized to GAPDH. There were significant differences for the treatment compared with the negative control (NC) group of oligonucleotide transfection (**p < 0.01, ****p < 0.0001).
Fig. 1 CD44 expression in bladder tissues and cells and effective Bcl2-siRNA sequences that were screened. A: Immunohistochemistry assays were performed to detect CD44 receptor expression in bladder tumours and normal tissues. B: CD44 expression in bladder cancer cell lines (T24, 5637) and the normal bladder cell line (SV-HUC-1) was detected by western blotting. C: The effective interference sequences were screened for the down regulation of the targeted gene, Bcl2. The siRNA1, 2, 3 are targeted to the sites of 528, 928, 1014 of Bcl2 respectively. All quantification of protein levels was normalized to GAPDH. There were significant differences for the treatment compared with the negative control (NC) group of oligonucleotide transfection (**p < 0.01, ****p < 0.0001).CC BY-NC-ND · PubMed Central
Fig. 2 Characterizations of HAD and siRNA@CS-HAD NPs. A: FTIR spectroscopy of Hyaluronic acid dialdehyde (HAD). B: The morphology of the nanoparticles detected by SEM. C: The particle size distribution of siRNA@CS NPs with or without HAD modification. D: Their stability analysis, the particle size, polydispersity index (PDI) and zeta potential were recorded for 6 days.
Fig. 2 Characterizations of HAD and siRNA@CS-HAD NPs. A: FTIR spectroscopy of Hyaluronic acid dialdehyde (HAD). B: The morphology of the nanoparticles detected by SEM. C: The particle size distribution of siRNA@CS NPs with or without HAD modification. D: Their stability analysis, the particle size, polydispersity index (PDI) and zeta potential were recorded for 6 days.CC BY-NC-ND · PubMed Central
Fig. 3 Characterizations of siRNA@CS-HAD NPs and effect on cells. A: The loading efficiency of siRNA@CS-HAD NPs with different amounts of encapsulated siRNA (0.5 or 1.5 OD) determined by agarose gel electrophoresis, the tested nanoparticles' concentration was adjusted by siRNA loading degree. B: TGA analysis performed to determine the modification of HA. C: The cytotoxicity of CS NPs and CS-HAD NPs towards L929 (healthy cells) at 24, 48 and 96 h. D: The cell viability of bladder cancer cells with different nanoparticle treated 96h. E: Detection the cleavage of executioner caspase substrate PARP by western blotting after that T24 cells were cultured for 8, 24 and 48h with siRNA@CS-HAD NPs. Quantification of the protein level was normalized to GAPDH. ****p < 0.0001 indicates a highly significantly difference.
Fig. 3 Characterizations of siRNA@CS-HAD NPs and effect on cells. A: The loading efficiency of siRNA@CS-HAD NPs with different amounts of encapsulated siRNA (0.5 or 1.5 OD) determined by agarose gel electrophoresis, the tested nanoparticles' concentration was adjusted by siRNA loading degree. B: TGA analysis performed to determine the modification of HA. C: The cytotoxicity of CS NPs and CS-HAD NPs towards L929 (healthy cells) at 24, 48 and 96 h. D: The cell viability of bladder cancer cells with different nanoparticle treated 96h. E: Detection the cleavage of executioner caspase substrate PARP by western blotting after that T24 cells were cultured for 8, 24 and 48h with siRNA@CS-HAD NPs. Quantification of the protein level was normalized to GAPDH. ****p < 0.0001 indicates a highly significantly difference.CC BY-NC-ND · PubMed Central
Fig. 4 Evaluation of targeting nanoparticles’ interference effects. A: The fluorescence microscopy observation and protein expression comparisons of the interference effect between targeting nanoparticle (CS-HAD NPs) and a commercial transfection reagent (HiPerFect) containing 1 or 2 μl cy3-siRNA (20μΜ), respectively. B: Flow cytometry was performed to evaluate the transfection rates after treatment for 24h. C: Fluorescence microscopy observation after siRNA@CS-HAD NPs treatment for different times. All the red fluorescence is from cy3-labeled siRNA. D: Interference effects and CD44 receptor activation were detected by western blotting at different time points treated with siRNA@CS-HAD NPs. Quantification of the protein level was normalized to GAPDH. **p < 0.01 indicates a highly significantly difference.
Fig. 4 Evaluation of targeting nanoparticles’ interference effects. A: The fluorescence microscopy observation and protein expression comparisons of the interference effect between targeting nanoparticle (CS-HAD NPs) and a commercial transfection reagent (HiPerFect) containing 1 or 2 μl cy3-siRNA (20μΜ), respectively. B: Flow cytometry was performed to evaluate the transfection rates after treatment for 24h. C: Fluorescence microscopy observation after siRNA@CS-HAD NPs treatment for different times. All the red fluorescence is from cy3-labeled siRNA. D: Interference effects and CD44 receptor activation were detected by western blotting at different time points treated with siRNA@CS-HAD NPs. Quantification of the protein level was normalized to GAPDH. **p < 0.01 indicates a highly significantly difference.CC BY-NC-ND · PubMed Central
Fig. 5 Evaluation of CD44 receptor activation. A, B: Fluorescence was observed by confocal microscopy under different magnifications after cells were treated with siRNA@CS-HAD NPs. The red fluorescence was cy3-siRNA loaded by the nanoparticles, and the green fluorescence was FITC-stained CD44 with antibody. C: The interference effect of the targeted gene, Bcl2, was detected by qPCR. (*p < 0.05, ****p < 0.0001).
Fig. 5 Evaluation of CD44 receptor activation. A, B: Fluorescence was observed by confocal microscopy under different magnifications after cells were treated with siRNA@CS-HAD NPs. The red fluorescence was cy3-siRNA loaded by the nanoparticles, and the green fluorescence was FITC-stained CD44 with antibody. C: The interference effect of the targeted gene, Bcl2, was detected by qPCR. (*p < 0.05, ****p < 0.0001).CC BY-NC-ND · PubMed Central
Fig. 6 Endosomal escape analysis of the intracellular uptaken siRNA@CS-HAD NPs in bladder cancer cells. A: Confocal microscopy images after T24 cells culturing with siRNA@CS-HAD NPs for 1h, 2h, 4h and 6h. The red fluorescence was the cy3-siRNA loaded by nanoparticles, lysosomes were labeled in green fluorescence with Lysotraker staining, and the nuclei were stained blue with DAPI. B: At least 3 images for each group were selected for overlap fluorescence analysis by Image J software.
Fig. 6 Endosomal escape analysis of the intracellular uptaken siRNA@CS-HAD NPs in bladder cancer cells. A: Confocal microscopy images after T24 cells culturing with siRNA@CS-HAD NPs for 1h, 2h, 4h and 6h. The red fluorescence was the cy3-siRNA loaded by nanoparticles, lysosomes were labeled in green fluorescence with Lysotraker staining, and the nuclei were stained blue with DAPI. B: At least 3 images for each group were selected for overlap fluorescence analysis by Image J software.CC BY-NC-ND · PubMed Central
Fig. 7 In vivo anti-tumour effects of the nanoparticles in a xenograft model. A: Clotting indexes of materials were analysed. Plasma prothrombin time (PT), activated partial prothrombin time (APTT), thrombin time (TT) and plasma fibrinogen (Fbg) were measured by an automatic coagulation analyser. The same amounts of PBS were used as the control. The experiments were performed in triplicate. B: After intravenous injection for 20 days, all mice in the four groups of PBS (control), siRNA@CS-HAD NPs, siRNA@CS NPs and naked cy3-siRNA were sacrificed, and the tumours were collected. C: The tumour size was regularly measured and calculated every 5 days. D: The weights of animals and tumours were obtained, and the tumour weight index was calculated by the ratio of the tumour weight to the body weight. E: The liver, spleen and kidney tissues were completely isolated and weighed to calculate organ indexes by the ratio of the tissue (liver, kidney, and spleen) weight to the body weight. *p < 0.05 indicates significant differences, and **p < 0.01 indicates highly significant differences.
Fig. 7 In vivo anti-tumour effects of the nanoparticles in a xenograft model. A: Clotting indexes of materials were analysed. Plasma prothrombin time (PT), activated partial prothrombin time (APTT), thrombin time (TT) and plasma fibrinogen (Fbg) were measured by an automatic coagulation analyser. The same amounts of PBS were used as the control. The experiments were performed in triplicate. B: After intravenous injection for 20 days, all mice in the four groups of PBS (control), siRNA@CS-HAD NPs, siRNA@CS NPs and naked cy3-siRNA were sacrificed, and the tumours were collected. C: The tumour size was regularly measured and calculated every 5 days. D: The weights of animals and tumours were obtained, and the tumour weight index was calculated by the ratio of the tumour weight to the body weight. E: The liver, spleen and kidney tissues were completely isolated and weighed to calculate organ indexes by the ratio of the tissue (liver, kidney, and spleen) weight to the body weight. *p < 0.05 indicates significant differences, and **p < 0.01 indicates highly significant differences.CC BY-NC-ND · PubMed Central
Fig. 8 Detection of targeting effects in vivo. A: The fluorescence intensities of tumour-bearing mice were monitored after 4 h of the last injection to detect the targeting effect. B: Immunofluorescence observation under the same exposure for each fluorescent channel after siRNA@CS-HAD NPs, naked siRNA, and siRNA@CS NPs treatment compared with the control group of PBS. C: The protein expression of Bcl-2 was analysed by western blotting. Quantification of the protein level was normalized to GAPDH. *p < 0.05 indicates significant differences.
Fig. 8 Detection of targeting effects in vivo. A: The fluorescence intensities of tumour-bearing mice were monitored after 4 h of the last injection to detect the targeting effect. B: Immunofluorescence observation under the same exposure for each fluorescent channel after siRNA@CS-HAD NPs, naked siRNA, and siRNA@CS NPs treatment compared with the control group of PBS. C: The protein expression of Bcl-2 was analysed by western blotting. Quantification of the protein level was normalized to GAPDH. *p < 0.05 indicates significant differences.CC BY-NC-ND · PubMed Central
Fig. 9 Detection of accumulation and metabolism of materials in the tumour and major organs. A, B: The fluorescence intensities were monitored and the percentage of fluorescence in each group were analysed. C: Immunofluorescence observation of the liver, spleen and kidney under the same exposure for each fluorescent channel after siRNA@CS-HAD NPs, naked siRNA and siRNA@CS NPs treatments compared with the control (PBS).
Fig. 9 Detection of accumulation and metabolism of materials in the tumour and major organs. A, B: The fluorescence intensities were monitored and the percentage of fluorescence in each group were analysed. C: Immunofluorescence observation of the liver, spleen and kidney under the same exposure for each fluorescent channel after siRNA@CS-HAD NPs, naked siRNA and siRNA@CS NPs treatments compared with the control (PBS).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 62

  1. Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, Ca - Cancer J. Clin., 68, 394, 10.3322/caac.21492 · DOI · Paper page
  2. Verma, 2017, Cluster of differentiation 44 (CD44) gene variants: a putative cancer stem cell marker in risk prediction of bladder cancer in north Indian population, Indian J. Clin. Biochem., 32, 74, 10.1007/s12291-016-0580-y · DOI
  3. Oeyen, 2019, Bladder cancer diagnosis and follow-up: the current status and possible role of extracellular vesicles, Int. J. Mol. Sci., 20, 10.3390/ijms20040821 · DOI
  4. Chen, 2018, A novel monoclonal antibody KMP1 has potential antitumor activity of bladder cancer by blocking CD44 in vivo and in vitro, Cancer Med, 7, 2064, 10.1002/cam4.1446 · DOI
  5. Funt, 2017, Systemic, perioperative management of muscle-invasive bladder cancer and future horizons, Nat. Rev. Clin. Oncol., 14, 221, 10.1038/nrclinonc.2016.188 · DOI
  6. Shah, 2011, New strategies in muscle-invasive bladder cancer: on the road to personalized medicine, Clin. Canc. Res., 17, 2608, 10.1158/1078-0432.CCR-10-2770 · DOI
  7. Lobo, 2017, Landmarks in the treatment of muscle-invasive bladder cancer, Nat. Rev. Urol., 14, 565, 10.1038/nrurol.2017.82 · DOI
  8. Yoshida, 2019, Predictive biomarkers for drug response in bladder cancer, Int. J. Urol. : official journal of the Japanese Urological Association, 26, 1044, 10.1111/iju.14082 · DOI
  9. Seidl, 2020, Targets for therapy of bladder cancer, Semin. Nucl. Med., 50, 162, 10.1053/j.semnuclmed.2020.02.006 · DOI
  10. Rahman, 2017, Systemic delivery of bc12-targeting siRNA by DNA nanoparticles suppresses cancer cell growth, Angew. Chem., 56, 16023, 10.1002/anie.201709485 · DOI
  11. Li, 2018, Bioreduction-ruptured nanogel for switch on/off release of Bcl2 siRNA in breast tumor therapy, J. Contr. Release : official journal of the Controlled Release Society, 292, 78, 10.1016/j.jconrel.2018.02.036 · DOI
  12. Liu, 2016, Synthetic Bax-Anti Bcl2 combination module actuated by super artificial hTERT promoter selectively inhibits malignant phenotypes of bladder cancer, J. Exp. Clin. Canc. Res., 35, 3, 10.1186/s13046-015-0279-6 · DOI
  13. Kim, 2016, Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines, Investigative and Clinical Urology, 57, 63, 10.4111/icu.2016.57.1.63 · DOI
  14. Cai, 2017, A hyaluronic acid-based hydrogel enabling CD44-mediated chondrocyte binding and gapmer oligonucleotide release for modulation of gene expression in osteoarthritis, J. Contr. Release : official journal of the Controlled Release Society, 253, 153, 10.1016/j.jconrel.2017.03.004 · DOI
  15. Howard, 2009, Delivery of RNA interference therapeutics using polycation-based nanoparticles, Adv. Drug Deliv. Rev., 61, 710, 10.1016/j.addr.2009.04.001 · DOI
  16. Verma, 1997, Gene therapy -- promises, problems and prospects, Nature, 389, 239, 10.1038/38410 · DOI · Paper page
  17. Merdan, 2002, Prospects for cationic polymers in gene and oligonucleotide therapy against cancer, Adv. Drug Deliv. Rev., 54, 715, 10.1016/S0169-409X(02)00046-7 · DOI
  18. Nakamura, 2018, Reducing the cytotoxicity of lipid nanoparticles associated with a fusogenic cationic lipid in a natural killer cell line by introducing a polycation-based siRNA core, Mol. Pharm., 15, 2142, 10.1021/acs.molpharmaceut.7b01166 · DOI
  19. Bernard, 2018, Biocompatibility of polymer-based biomaterials and medical devices - regulations, in vitro screening and risk-management, Biomaterials science, 6, 2025, 10.1039/C8BM00518D · DOI
  20. Liang, 2018, N-Acetyl-Glucosamine sensitizes non-small cell lung cancer cells to TRAIL-induced apoptosis by activating death receptor 5, cellular physiology and biochemistry, International journal of experimental cellular physiology, biochemistry, and pharmacology, 45, 2054, 10.1159/000488042 · DOI
  21. Liang, 2011, An in situ formed biodegradable hydrogel for reconstruction of the corneal endothelium, Colloids Surf. B Biointerfaces, 82, 1, 10.1016/j.colsurfb.2010.07.043 · DOI
  22. Liang, 2011, Fabrication and characters of a corneal endothelial cells scaffold based on chitosan, J. Mater. Sci. Mater. Med., 22, 175, 10.1007/s10856-010-4190-6 · DOI
  23. Zaki, 2011, Nanocarriers for cytoplasmic delivery: cellular uptake and intracellular fate of chitosan and hyaluronic acid-coated chitosan nanoparticles in a phagocytic cell model, Macromol. Biosci., 11, 1747, 10.1002/mabi.201100156 · DOI
  24. Borges, 2005, Preparation of coated nanoparticles for a new mucosal vaccine delivery system, Int. J. Pharm., 299, 155, 10.1016/j.ijpharm.2005.04.037 · DOI
  25. Borges, 2006, Uptake studies in rat Peyer's patches, cytotoxicity and release studies of alginate coated chitosan nanoparticles for mucosal vaccination, J. Contr. Release : official journal of the Controlled Release Society, 114, 348, 10.1016/j.jconrel.2006.06.011 · DOI
  26. Ghaz-Jahanian, 2015, Application of chitosan-based nanocarriers in tumor-targeted drug delivery, Mol. Biotechnol., 57, 201, 10.1007/s12033-014-9816-3 · DOI
  27. Zhong, 2014, Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy, Biomacromolecules, 15, 1955, 10.1021/bm5003009 · DOI
  28. Nascimento, 2014, Mad2 checkpoint gene silencing using epidermal growth factor receptor-targeted chitosan nanoparticles in non-small cell lung cancer model, Mol. Pharm., 11, 3515, 10.1021/mp5002894 · DOI
  29. Chen, 2018, The biology and role of CD44 in cancer progression: therapeutic implications, J. Hematol. Oncol., 11, 64, 10.1186/s13045-018-0605-5 · DOI · Paper page
  30. He, 2018, CD44 is overexpressed and correlated with tumor progression in gallbladder cancer, Canc. Manag. Res., 10, 3857
  31. Joshua, 2012, Frequency of cells expressing CD44, a head and neck cancer stem cell marker: correlation with tumor aggressiveness, Head Neck, 34, 42, 10.1002/hed.21699 · DOI
  32. Marhaba, 2004, CD44 in cancer progression: adhesion, migration and growth regulation, J. Mol. Histol., 35, 211, 10.1023/B:HIJO.0000032354.94213.69 · DOI
  33. Park, 2012, shRNA against CD44 inhibits cell proliferation, invasion and migration, and promotes apoptosis of colon carcinoma cells, Oncol. Rep., 27, 339
  34. Oldenburg, 2016, CD44 and RHAMM are essential for rapid growth of bladder cancer driven by loss of Glycogen Debranching Enzyme (AGL), BMC Canc., 16, 713, 10.1186/s12885-016-2756-5 · DOI
  35. Croll, 2006, A blank slate? Layer-by-layer deposition of hyaluronic acid and chitosan onto various surfaces, Biomacromolecules, 7, 1610, 10.1021/bm060044l · DOI
  36. Lord, 2009, Protein adsorption on derivatives of hyaluronic acid and subsequent cellular response, J. Biomed. Mater. Res., 91, 635, 10.1002/jbm.a.32219 · DOI
  37. Ouasti, 2012, The CD44/integrins interplay and the significance of receptor binding and re-presentation in the uptake of RGD-functionalized hyaluronic acid, Biomaterials, 33, 1120, 10.1016/j.biomaterials.2011.10.009 · DOI
  38. Peer, 2004, Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models, Int. J. Canc., 108, 780, 10.1002/ijc.11615 · DOI
  39. Mohan, 2017, Chitosan-hyaluronic acid hydrogel for cartilage repair, Int. J. Biol. Macromol., 104, 1936, 10.1016/j.ijbiomac.2017.03.142 · DOI
  40. Liu, 2015, Increased RIPK4 expression is associated with progression and poor prognosis in cervical squamous cell carcinoma patients, Sci. Rep., 5, 11955, 10.1038/srep11955 · DOI
  41. Desai, 2016, Chitosan nanoparticles prepared by ionotropic gelation: an overview of recent advances, Crit. Rev. Ther. Drug Carrier Syst., 33, 107, 10.1615/CritRevTherDrugCarrierSyst.2016014850 · DOI
  42. Koukaras, 2012, Insight on the formation of chitosan nanoparticles through ionotropic gelation with tripolyphosphate, Mol. Pharm., 9, 2856, 10.1021/mp300162j · DOI
  43. Goodwin, 2014, Bladder cancer stem cells: biological and therapeutic perspectives, Curr. Stem Cell Res. Ther., 9, 1
  44. Anand, 2019, CD44 splice variant (CD44v3) promotes progression of urothelial carcinoma of bladder through Akt/ERK/STAT3 pathways: novel therapeutic approach, J. Canc. Res. Clin. Oncol., 145, 2649, 10.1007/s00432-019-03024-9 · DOI
  45. Wu, 2018, Predictive value of CD44 in muscle-invasive bladder cancer and its relationship with IL-6 signaling, Ann. Surg Oncol., 25, 3518, 10.1245/s10434-018-6706-0 · DOI
  46. Wu, 2017, Impact of CD44 expression on radiation response for bladder cancer, J. Canc., 8, 1137, 10.7150/jca.18297 · DOI
  47. Li, 2015, Enhanced therapeutic siRNA to tumor cells by a pH-sensitive agmatine-chitosan bioconjugate, ACS Appl. Mater. Interfaces, 7, 8114, 10.1021/acsami.5b00851 · DOI
  48. Atala, 2017, Re: Mg(II)-Catechin nanoparticles delivering siRNA targeting EIF5A2 inhibit bladder cancer cell growth in vitro and in vivo, J. Urol., 198, 258
  49. Chen, 2014, Highly effective inhibition of lung cancer growth and metastasis by systemic delivery of siRNA via multimodal mesoporous silica-based nanocarrier, Biomaterials, 35, 10058, 10.1016/j.biomaterials.2014.09.003 · DOI
  50. Jiang, 2015, Targeted delivery of CXCR4-siRNA by scFv for HER2(+) breast cancer therapy, Biomaterials, 59, 77, 10.1016/j.biomaterials.2015.04.030 · DOI
  51. Fakhr, 2016, Precise and efficient siRNA design: a key point in competent gene silencing, Canc. Gene Ther., 23, 73, 10.1038/cgt.2016.4 · DOI
  52. Zhao, 2008, Bcl2 inhibits abasic site repair by down-regulating APE1 endonuclease activity, J. Biol. Chem., 283, 9925, 10.1074/jbc.M708345200 · DOI
  53. Westerhout, 2007, A systematic analysis of the effect of target RNA structure on RNA interference, Nucleic Acids Res., 35, 4322, 10.1093/nar/gkm437 · DOI
  54. Tan, 2014, Injectable in situ forming biodegradable chitosan-hyaluronic acid based hydrogels for adipose tissue regeneration, Organogenesis, 6, 173, 10.4161/org.6.3.12037 · DOI
  55. Nascimento, 2016, Biodistribution and pharmacokinetics of Mad2 siRNA-loaded EGFR-targeted chitosan nanoparticles in cisplatin sensitive and resistant lung cancer models, Nanomedicine, 11, 767, 10.2217/nnm.16.14 · DOI
  56. Jain, 2016, Fabrication, characterization and cytotoxicity studies of ionically cross-linked docetaxel loaded chitosan nanoparticles, Carbohydr. Polym., 137, 65, 10.1016/j.carbpol.2015.10.012 · DOI
  57. Almalik, 2013, Hyaluronic acid-coated chitosan nanoparticles: molecular weight-dependent effects on morphology and hyaluronic acid presentation, J. Contr. Release, 172, 1142, 10.1016/j.jconrel.2013.09.032 · DOI
  58. Singhal, 2002, Synthesis of blood compatible polyamide block copolymers, Biomaterials, 23, 1139, 10.1016/S0142-9612(01)00228-9 · DOI
  59. Li, 2001, Preparation and blood compatibility of polysiloxane/liquid-crystal composite membranes, Biomaterials, 22, 2595, 10.1016/S0142-9612(00)00222-2 · DOI
  60. Yuan, 2011, Enhanced accumulation of low-molecular-weight chitosan in kidneys: a study on the influence of N-acetylation of chitosan on the renal targeting, J. Drug Target., 19, 540, 10.3109/1061186X.2010.521158 · DOI
  61. Yuan, 2009, Specific renal uptake of randomly 50% N-acetylated low molecular weight chitosan, Mol. Pharm., 6, 305, 10.1021/mp800078a · DOI
  62. Zhang, 2018, Biomacromolecules as carriers in drug delivery and tissue engineering, Acta Pharm. Sin. B, 8, 34, 10.1016/j.apsb.2017.11.005 · DOI

Cited by

Sorted by citations

Metadata

Authors
Liang, Y., Wang, Y., Wang, L., Liang, Z., Li, D., Xu, X., Chen, Y., Yang, X., Zhang, H., & Niu, H.
Venue
Bioactive Materials
Publisher
Elsevier BV
Published
2021-02
Volume
6
Issue
2
Pages
433-446
ISSN
2452-199X
DOI
10.1016/j.bioactmat.2020.08.019
PMC
PMC7490593
Cited by
101
References
2
Language
en
Update notices
erratum (2024-10-01)
Licence
Funders
  • National Natural Science Foundation of China (81772713, 81472411, 81401899, 81372752)
  • Taishan Scholar Program of Shandong Province (tsqn20161077)
  • Key Research and Development Program of Shandong Province (2018GSF118197)
  • China Postdoctoral Science Foundation (2017M622144)
  • Qingdao Postdoctoral Application Research Project
  • Academy of Finland (328933)
  • Sigrid Juselius Foundation (28002247K1)
  • Qingdao University

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review